Trial Profile
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary) ; Cefalexin; Fluconazole; Midazolam; Posaconazole; Voriconazole
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms CHRYSALIS
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 17 Jun 2021 Results of retrospective analysis assessing whether prior TKI therapy affected response and survival in (phase 1/2 CHRYSALIS (n=145) and phase 3 ADMIRAL (n=371)) these two trials, presented at the 26th Congress of the European Haematology Association.
- 07 Jun 2021 According to an Astellas Pharma media release, results of retrospective analysis assessing clinical outcomes from CHRYSALIS and ADMIRAL studies were presented at he European Hematology Association (EHA) virtual congress 2021.
- 08 Dec 2020 Results of retrospective analysis assessing clinical outcomes from CHRYSALIS and ADMIRAL sudies presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology